Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2009

Open Access 01-12-2009 | Primary research

The human immunodeficiency virus type 1 Vpr protein and its carboxy-terminally truncated form induce apoptosis in tumor cells

Authors: Mizuho Nonaka, Yoshie Hashimoto, Shin-nosuke Takeshima, Yoko Aida

Published in: Cancer Cell International | Issue 1/2009

Login to get access

Abstract

The human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces apoptosis after cell cycle arrest at the G2 phase in primate cells. We have reported previously that C81, a carboxy-terminally truncated form of Vpr, interferes with cell proliferation and results in apoptosis without G2 arrest. Here, we investigated whether this property of Vpr and C81 could be exploited for use as a potential anticancer agent. First, we demonstrated that C81 induced G1 arrest and apoptosis in all tumor cells tested. In contrast, Vpr resulted in G2 arrest and apoptosis in HeLa and 293 T cells. Vpr also suppressed the damaged-DNA-specific binding protein 1 (DDB1) in HepG2 cells, thereby inducing apoptosis without G2 arrest. G2 arrest was restored when DDB1 was overexpressed in cells that also expressed Vpr. Surprisingly, C81 induced G2 arrest when DDB1 was overexpressed in HepG2 cells, but not in HeLa or 293 T cells. Thus, the induction of Vpr- and C81-mediated cell cycle arrest appears to depend on the cell type, whereas apoptosis was observed in all tumor cells tested. Overall, Vpr and C81 have potential as novel therapeutic agents for treatment of cancer.
Appendix
Available only for authorised users
Literature
1.
Aida Y, Matsuda G: Role of Vpr in HIV-1 nuclear import: therapeutic implications. Curr HIV Res. 2009, 7 (2): 136-143. 10.2174/157016209787581418.CrossRefPubMed
2.
Heinzinger NK, Bukinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Lee MA, Gendelman HE, Ratner L, Stevenson M, Emerman M: The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA. 1994, 91 (15): 7311-7315. 10.1073/pnas.91.15.7311.PubMedCentralCrossRefPubMed
3.
Kamata M, Nitahara-Kasahara Y, Miyamoto Y, Yoneda Y, Aida Y: Importin-alpha promotes passage through the nuclear pore complex of human immunodeficiency virus type 1 Vpr. J Virol. 2005, 79 (6): 3557-3564. 10.1128/JVI.79.6.3557-3564.2005.PubMedCentralCrossRefPubMed
4.
Nitahara-Kasahara Y, Kamata M, Yamamoto T, Zhang X, Miyamoto Y, Muneta K, Iijima S, Yoneda Y, Tsunetsugu-Yokota Y, Aida Y: Novel nuclear import of Vpr promoted by importin alpha is crucial for human immunodeficiency virus type 1 replication in macrophages. J Virol. 2007, 81 (10): 5284-5293. 10.1128/JVI.01928-06.PubMedCentralCrossRefPubMed
5.
Kino T, Gragerov A, Slobodskaya O, Tsopanomichalou M, Chrousos GP, Pavlakis GN: Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators. J Virol. 2002, 76 (19): 9724-9734. 10.1128/JVI.76.19.9724-9734.2002.PubMedCentralCrossRefPubMed
6.
Hashizume C, Kuramitsu M, Zhang X, Kurosawa T, Kamata M, Aida Y: Human immunodeficiency virus type 1 Vpr interacts with spliceosomal protein SAP145 to mediate cellular pre-mRNA splicing inhibition. Microbes Infect. 2007, 9 (4): 490-497. 10.1016/j.micinf.2007.01.013.CrossRefPubMed
7.
Kuramitsu M, Hashizume C, Yamamoto N, Azuma A, Kamata M, Tanaka Y, Aida Y: A novel role for Vpr of human immunodeficiency virus type 1 as a regulator of the splicing of cellular pre-mRNA. Microbes Infect. 2005, 7 (9-10): 1150-1160. 10.1016/j.micinf.2005.03.022.CrossRefPubMed
8.
Zhang X, Aida Y: HIV-1 Vpr: a novel role in regulating RNA splicing. Curr HIV Res. 2009, 7 (2): 163-168. 10.2174/157016209787581517.CrossRefPubMed
9.
Andersen JL, Planelles V: The role of Vpr in HIV-1 pathogenesis. Curr HIV Res. 2005, 3 (1): 43-51. 10.2174/1570162052772988.CrossRefPubMed
10.
11.
Felzien LK, Woffendin C, Hottiger MO, Subbramanian RA, Cohen EA, Nabel GJ: HIV transcriptional activation by the accessory protein, VPR, is mediated by the p300 co-activator. Proc Natl Acad Sci USA. 1998, 95 (9): 5281-5286. 10.1073/pnas.95.9.5281.PubMedCentralCrossRefPubMed
12.
Goh WC, Rogel ME, Kinsey CM, Michael SF, Fultz PN, Nowak MA, Hahn BH, Emerman M: HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med. 1998, 4 (1): 65-71. 10.1038/nm0198-065.CrossRefPubMed
13.
Planelles V, Jowett JB, Li QX, Xie Y, Hahn B, Chen IS: Vpr-induced cell cycle arrest is conserved among primate lentiviruses. J Virol. 1996, 70 (4): 2516-2524.PubMedCentralPubMed
14.
Stivahtis GL, Soares MA, Vodicka MA, Hahn BH, Emerman M: Conservation and host specificity of Vpr-mediated cell cycle arrest suggest a fundamental role in primate lentivirus evolution and biology. J Virol. 1997, 71 (6): 4331-4338.PubMedCentralPubMed
15.
Zimmerman ES, Chen J, Andersen JL, Ardon O, Dehart JL, Blackett J, Choudhary SK, Camerini D, Nghiem P, Planelles V: Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation. Mol Cell Biol. 2004, 24 (21): 9286-9294. 10.1128/MCB.24.21.9286-9294.2004.PubMedCentralCrossRefPubMed
16.
Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, Mundt P, Williams SA, Warmerdam M, Kahn J, Hecht FM, Grant RM, de Noronha CM, Weyrich AS, Greene WC, Planelles V: Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol. 2006, 80 (21): 10407-10418. 10.1128/JVI.01212-06.PubMedCentralCrossRefPubMed
17.
McGowan CH, Russell P: The DNA damage response: sensing and signaling. Curr Opin Cell Biol. 2004, 16 (6): 629-633. 10.1016/j.ceb.2004.09.005.CrossRefPubMed
18.
Le Rouzic E, Belaidouni N, Estrabaud E, Morel M, Rain JC, Transy C, Margottin-Goguet F: HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle. 2007, 6 (2): 182-188.CrossRefPubMed
19.
Angers S, Li T, Yi X, MacCoss MJ, Moon RT, Zheng N: Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature. 2006, 443 (7111): 590-593.PubMed
20.
He YJ, McCall CM, Hu J, Zeng Y, Xiong Y: DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases. Genes Dev. 2006, 20 (21): 2949-2954. 10.1101/gad.1483206.PubMedCentralCrossRefPubMed
21.
Higa LA, Wu M, Ye T, Kobayashi R, Sun H, Zhang H: CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation. Nat Cell Biol. 2006, 8 (11): 1277-1283. 10.1038/ncb1490.CrossRefPubMed
22.
Jin J, Arias EE, Chen J, Harper JW, Walter JC: A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol Cell. 2006, 23 (5): 709-721. 10.1016/j.molcel.2006.08.010.CrossRefPubMed
23.
Belzile JP, Duisit G, Rougeau N, Mercier J, Finzi A, Cohen EA: HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase. PLoS Pathog. 2007, 3 (7): e85-10.1371/journal.ppat.0030085.PubMedCentralCrossRefPubMed
24.
DeHart JL, Zimmerman ES, Ardon O, Monteiro-Filho CM, Arganaraz ER, Planelles V: HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol J. 2007, 4: 57-10.1186/1743-422X-4-57.PubMedCentralCrossRefPubMed
25.
Hrecka K, Gierszewska M, Srivastava S, Kozaczkiewicz L, Swanson SK, Florens L, Washburn MP, Skowronski J: Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proc Natl Acad Sci USA. 2007, 104 (28): 11778-11783. 10.1073/pnas.0702102104.PubMedCentralCrossRefPubMed
26.
Schrofelbauer B, Hakata Y, Landau NR: HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1. Proc Natl Acad Sci USA. 2007, 104 (10): 4130-4135. 10.1073/pnas.0610167104.PubMedCentralCrossRefPubMed
27.
Wen X, Duus KM, Friedrich TD, de Noronha CM: The HIV1 protein Vpr acts to promote G2 cell cycle arrest by engaging a DDB1 and Cullin4A-containing ubiquitin ligase complex using VprBP/DCAF1 as an adaptor. J Biol Chem. 2007, 282 (37): 27046-27057. 10.1074/jbc.M703955200.CrossRefPubMed
28.
Dehart JL, Planelles V: Human immunodeficiency virus type 1 Vpr links proteasomal degradation and checkpoint activation. J Virol. 2008, 82 (3): 1066-1072. 10.1128/JVI.01628-07.PubMedCentralCrossRefPubMed
29.
Muthumani K, Zhang D, Hwang DS, Kudchodkar S, Dayes NS, Desai BM, Malik AS, Yang JS, Chattergoon MA, Maguire HC, Weiner DB: Adenovirus encoding HIV-1 Vpr activates caspase 9 and induces apoptotic cell death in both p53 positive and negative human tumor cell lines. Oncogene. 2002, 21 (30): 4613-4625. 10.1038/sj.onc.1205549.CrossRefPubMed
30.
Stewart SA, Poon B, Jowett JB, Xie Y, Chen IS: Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells. Proc Natl Acad Sci USA. 1999, 96 (21): 12039-12043. 10.1073/pnas.96.21.12039.PubMedCentralCrossRefPubMed
31.
Siddiqui K, Del Valle L, Morellet N, Cui J, Ghafouri M, Mukerjee R, Urbanska K, Fan S, Pattillo CB, Deshmane SL, Kiani MF, Ansari R, Khalili K, Roques BP, Reiss K, Bouaziz S, Amini S, Srinivasan A, Sawaya BE: Molecular mimicry in inducing DNA damage between HIV-1 Vpr and the anticancer agent, cisplatin. Oncogene. 2008, 27 (1): 32-43. 10.1038/sj.onc.1210632.CrossRefPubMed
32.
McCray AN, Ugen KE, Heller R: Enhancement of anti-melanoma activity of a plasmid expressing HIV-1 Vpr delivered through in vivo electroporation. Cancer Biol Ther. 2007, 6 (8): 1269-1275.CrossRefPubMed
33.
McCray AN, Ugen KE, Muthumani K, Kim JJ, Weiner DB, Heller R: Complete regression of established subcutaneous B16 murine melanoma tumors after delivery of an HIV-1 Vpr-expressing plasmid by in vivo electroporation. Mol Ther. 2006, 14 (5): 647-655. 10.1016/j.ymthe.2006.06.010.CrossRefPubMed
34.
Azuma A, Matsuo A, Suzuki T, Kurosawa T, Zhang X, Aida Y: Human immunodeficiency virus type 1 Vpr induces cell cycle arrest at the G(1) phase and apoptosis via disruption of mitochondrial function in rodent cells. Microbes Infect. 2006, 8 (3): 670-679. 10.1016/j.micinf.2005.09.002.CrossRefPubMed
35.
Nishizawa M, Kamata M, Katsumata R, Aida Y: A carboxy-terminally truncated form of the human immunodeficiency virus type 1 Vpr protein induces apoptosis via G(1) cell cycle arrest. J Virol. 2000, 74 (13): 6058-6067. 10.1128/JVI.74.13.6058-6067.2000.PubMedCentralCrossRefPubMed
36.
Morellet N, Bouaziz S, Petitjean P, Roques BP: NMR structure of the HIV-1 regulatory protein VPR. J Mol Biol. 2003, 327 (1): 215-227. 10.1016/S0022-2836(03)00060-3.CrossRefPubMed
37.
Le Rouzic E, Morel M, Ayinde D, Belaidouni N, Letienne J, Transy C, Margottin-Goguet F: Assembly with the Cul4A-DDB1DCAF1 ubiquitin ligase protects HIV-1 Vpr from proteasomal degradation. J Biol Chem. 2008, 283 (31): 21686-21692. 10.1074/jbc.M710298200.CrossRefPubMed
38.
Zhao LJ, Mukherjee S, Narayan O: Biochemical mechanism of HIV-I Vpr function. Specific interaction with a cellular protein. J Biol Chem. 1994, 269 (22): 15577-15582.PubMed
39.
Nishizawa M, Kamata M, Mojin T, Nakai Y, Aida Y: Induction of apoptosis by the Vpr protein of human immunodeficiency virus type 1 occurs independently of G(2) arrest of the cell cycle. Virology. 2000, 276 (1): 16-26. 10.1006/viro.2000.0534.CrossRefPubMed
40.
Nishizawa M, Myojin T, Nishino Y, Nakai Y, Kamata M, Aida Y: A carboxy-terminally truncated form of the Vpr protein of human immunodeficiency virus type 1 retards cell proliferation independently of G(2) arrest of the cell cycle. Virology. 1999, 263 (2): 313-322. 10.1006/viro.1999.9905.CrossRefPubMed
41.
Nishino Y, Myojin T, Kamata M, Aida Y: Human immunodeficiency virus type 1 Vpr gene product prevents cell proliferation on mouse NIH3T3 cells without the G2 arrest of the cell cycle. Biochem Biophys Res Commun. 1997, 232 (2): 550-554. 10.1006/bbrc.1997.6186.CrossRefPubMed
42.
Cormack BP, Valdivia RH, Falkow S: FACS-optimized mutants of the green fluorescent protein (GFP). Gene. 1996, 173 (1 Spec No): 33-38. 10.1016/0378-1119(95)00685-0.CrossRefPubMed
43.
Gey GO, Coffman WD, Kubicek MT: Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium. Cancer Res. 1952, 12 (4): 264-265.
44.
Goldstein MN, Slotnick IJ, Journey LJ: In vitro studies with HeLa cell line sensitive and resistant to actinomycin D. Ann N Y Acad Sci. 1960, 89: 474-483. 10.1111/j.1749-6632.1960.tb20171.x.CrossRefPubMed
45.
DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP: Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol. 1987, 7 (1): 379-387.PubMedCentralCrossRefPubMed
46.
Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB: Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature. 1979, 282 (5739): 615-616. 10.1038/282615a0.CrossRefPubMed
47.
Knowles BB, Howe CC, Aden DP: Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science. 1980, 209 (4455): 497-499. 10.1126/science.6248960.CrossRefPubMed
48.
R-Development-Core-Team: R: A language and environment for statistical computing. 2008, Vienna, Austria: R Foundation for Statistical Computing, 2.8
Metadata
Title
The human immunodeficiency virus type 1 Vpr protein and its carboxy-terminally truncated form induce apoptosis in tumor cells
Authors
Mizuho Nonaka
Yoshie Hashimoto
Shin-nosuke Takeshima
Yoko Aida
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2009
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-9-20

Other articles of this Issue 1/2009

Cancer Cell International 1/2009 Go to the issue

Primary research

Abnormal expression, localization and interaction of canonical transient receptor potential ion channels in human breast cancer cell lines and tissues: a potential target for breast cancer diagnosis and therapy

Hypothesis

A reason why the ERBB2 gene is amplified and not mutated in breast cancer

Primary research

Eurycomanone induce apoptosis in HepG2 cells via up-regulation of p53

Primary research

Induction of apoptosis in HeLa cells by chloroform fraction of seed extracts of Nigella sativa

Primary research

INTS6/DICE1 inhibits growth of human androgen-independent prostate cancer cells by altering the cell cycle profile and Wnt signaling

Primary research

The mRNA expression of SATB1 and SATB2 in human breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits